Serum sickness in a multiple sclerosis patient treated with ocrelizumab

J Neurol. 2024 Feb;271(2):727-728. doi: 10.1007/s00415-023-12082-6. Epub 2023 Oct 31.

Authors

Vittorio Mantero¹, Christian Cordano², Roberto Balgera³, Paola Basilico³, Giovanni Novi⁴, Andrea Salmaggi³

Affiliations

¹ MS Center, Department of Neurology, ASST Lecco, Via dell'Eremo 9/11, 23900, Lecco, Italy. vittorio.mantero@hotmail.com.
² UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
³ MS Center, Department of Neurology, ASST Lecco, Via dell'Eremo 9/11, 23900, Lecco, Italy.
⁴ Department of Neurosciences, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

PMID: 37907726
DOI: 10.1007/s00415-023-12082-6

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Humans
Immunologic Factors / adverse effects
Multiple Sclerosis* / complications
Multiple Sclerosis* / drug therapy
Multiple Sclerosis, Chronic Progressive*
Multiple Sclerosis, Relapsing-Remitting* / complications
Multiple Sclerosis, Relapsing-Remitting* / drug therapy
Serum Sickness*

Substances

ocrelizumab
Antibodies, Monoclonal, Humanized
Immunologic Factors